サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363322

感染症治療の市場規模、シェア、動向分析：疾患タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年

Infectious Disease Therapeutics Market Size, Share & Trends Analysis By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV), By End-use (Hospital, Clinics), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 81 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
感染症治療の市場規模、シェア、動向分析：疾患タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月27日
発行: Grand View Research
ページ情報: 英文 81 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

感染症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の感染症治療市場規模は、2023年から2030年にかけてCAGR 7.1％を記録し、2030年までに1,152億米ドルに達すると予測されています。

同市場は主に、ヒト免疫不全ウイルス（HIV）、ヒトパピローマウイルス（HPV）、結核、肝炎の症例数が世界的に増加していることが要因となっています。

政府機関や民間企業は、感染症の予防、診断、治療のためにヘルスケア分野に多額の投資を行っており、感染症を治療するための新薬開拓への投資の増加や、これらの疾患に関する意識向上のためのイニシアチブの増加が、予測期間中に市場を押し上げると予想されます。さらに、特許切れの増加やジェネリック医薬品の市場参入は、価格の安さから感染症治療の需要を高めると予想されます。

さらに、これらの感染症の診断と治療に対する償還が利用可能であり、これらの疾患の発生率が高い地域でメーカーが医薬品を無料で配布していることも、市場の成長をさらに促進する要因として期待されています。しかし、抗感染症薬の普及率の低さ、偽造薬の多さが、予測期間中の市場成長抑制要因になると予想されます。

北米市場は2016年に最大のシェアを占めました。多数のメーカーの存在、有利な償還シナリオ、医療費の増加が、この地域が最大のシェアを占める主な要因です。しかし、アジア太平洋地域は2017年から2025年にかけて最も高い成長率を示す可能性が高いです。感染症の有病率の高さ、アジア諸国の経済状況の改善、感染症治療の採用を増やすための政府のイニシアティブの高まり、資金調達活動の活発化などが、予測期間中にこの地域の成長率が最も高くなる要因です。

感染症治療市場のレポートハイライト

  • HIV分野は2022年に31.6%の最大収益シェアを占めました。HIVの有病率の増加、HIV感染患者への資金援助活動の活発化、アフリカ諸国におけるHIV自己検査キットの無料供給の増加、世界中で啓発キャンペーンが行われていることなどが、このセグメントが最大のシェアを占めている主な要因です。
  • HPV分野は、予測期間中に8.1%のCAGRで最も速い成長が見込まれています。その成長の主な要因には、HPVの有病率の増加と、この感染症の治療に使用される薬剤の低価格化が含まれます。
  • 病院セグメントは、2022年に54.5%の最大の売上シェアを占めました。感染症を報告する緊急病院受診の増加が、市場の重要な成長要因となっています。
  • 北米が2022年に39.9%の最大収益シェアを占めました。このような疾患の有病率の増加と有利な償還シナリオは、同地域の感染症治療需要を促進する主な要因です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 感染症治療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 感染症治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 感染症治療：疾患タイプ別推定・動向分析

  • 感染症治療市場：重要なポイント
  • 感染症治療市場：動向と市場シェア分析、2022年および2030年
  • HIV
  • 肝炎
  • インフルエンザ
  • 結核
  • マラリア
  • HPV

第5章 感染症治療：最終使用別推定・動向分析

  • 感染症治療市場：重要なポイント
  • 感染症治療市場：動向と市場シェア分析、2022年および2030年
  • 病院
  • クリニック
  • その他

第6章 感染症治療市場：地域別推定・動向分析

  • 地域別の展望
  • 地域別の感染症治療市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • Novartis AG
    • Gilead
    • GlaxoSmithKline plc
    • Janssen Pharmaceutical, Inc.
    • F. Hoffmann-La Roche Ltd.
    • BioCryst Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim GmbH
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 3 North America infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 4 North America infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 5 U.S. infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 6 U.S. infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 7 Canada infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 8 Canada infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 9 Europe infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 10 Europe infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 11 Europe infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 12 Germany infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 13 Germany infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 UK infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 15 UK infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 16 France infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 17 France infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 18 Italy infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 19 Italy infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 20 Spain infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 21 Spain infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 22 Denmark infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 23 Denmark infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 24 Sweden infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 25 Sweden infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 26 Norway infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 27 Norway infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 28 Asia Pacific infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 29 Asia Pacific infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 31 Japan infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 32 Japan infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 China infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 34 China infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 35 India infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 36 India infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 37 Australia infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 38 Australia infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 39 Thailand infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 40 Thailand infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 41 South Korea infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 42 South Korea infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 43 Latin America infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 44 Latin America infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 45 Latin America infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 46 Brazil infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 47 Brazil infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 48 Mexico infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 49 Mexico infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 50 Argentina infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 51 Argentina infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 52 Middle East and Africa infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 53 Middle East and Africa infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 54 Middle East and Africa infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 55 South Africa infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 56 South Africa infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 57 Saudi Arabia infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 58 Saudi Arabia infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 59 UAE infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 60 UAE infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
  • Table 61 Kuwait infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
  • Table 62 Kuwait infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Infectious disease therapeutics: Market outlook
  • Fig. 8 Infectious disease therapeutics: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Industry value chain analysis
  • Fig. 13 Infectious disease therapeutics market driver impact
  • Fig. 14 Infectious disease therapeutics market restraint impact
  • Fig. 15 Infectious disease therapeutics market strategic initiatives analysis
  • Fig. 16 Infectious disease therapeutics market: Disease type movement analysis
  • Fig. 17 Infectious disease therapeutics market: Disease type outlook and key takeaways
  • Fig. 18 HIV market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 19 Hepatitis market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Influenza market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 TB market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Malaria market estimates and forecasts, 2018 - 2030
  • Fig. 23 HPV market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Infectious disease therapeutics market: End Use movement analysis
  • Fig. 25 Infectious disease therapeutics market: End Use outlook and key takeaways
  • Fig. 26 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 27 Clinics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Global infectious disease therapeutics market: Regional movement analysis
  • Fig. 30 Global infectious disease therapeutics market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)
目次
Product Code: GVR-1-68038-580-9

Infectious Disease Therapeutics Market Growth & Trends:

The global infectious disease therapeutics market size is expected to reach USD 115.2 billion by 2030, registering a CAGR of 7.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Infectious Disease Therapeutics Market Report Highlights:

  • The HIV segment held the largest revenue share of 31.6% in 2022. The increasing prevalence of HIV, rising funding activities for patients who have HIV, increasing supply of free HIV self-test kits in African countries, and raising awareness campaigns around the globe are the key factors responsible for the largest share held by this segment.
  • The HPV segment is expected to grow at the fastest CAGR of 8.1% during the forecast period. Major factors that are responsible for its growth include the increasing prevalence of HPV and the low cost of drugs that are used in the treatment of this infection.
  • The hospital's segment held the largest revenue share of 54.5% in 2022. The increasing number of emergency hospital visits reporting infectious diseases is a significant growth factor for the market.
  • North America dominated the market with the largest revenue share of 39.9% in 2022. The increasing prevalence of such disorders and favorable reimbursement scenarios are key factors likely to propel the region's demand for infectious disease therapeutics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease Type
    • 1.1.2. End use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease Type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Infectious Disease Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Infectious Disease Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Infectious Disease Therapeutics: Disease Type Estimates & Trend Analysis

  • 4.1. Infectious Disease Therapeutics Market: Key Takeaways
  • 4.2. Infectious Disease Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. HIV
    • 4.3.1. HIV market estimates and forecasts, 2018 to 2030, (USD Billion)
  • 4.4. Hepatitis
    • 4.4.1. Hepatitis market estimates and forecasts, 2018 to 2030, (USD Billion)
  • 4.5. Influenza
    • 4.5.1. Influenza market estimates and forecasts, 2018 to 2030, (USD Billion)
  • 4.6. TB
    • 4.6.1. TB market estimates and forecasts, 2018 to 2030, (USD Billion)
  • 4.7. Malaria
    • 4.7.1. Malaria market estimates and forecasts, 2018 to 2030, (USD Billion)
  • 4.8. HPV
    • 4.8.1. HPV market estimates and forecasts, 2018 to 2030, (USD Billion)

Chapter 5. Infectious Disease Therapeutics: End Use Estimates & Trend Analysis

  • 5.1. Infectious Disease Therapeutics Market: Key Takeaways
  • 5.2. Infectious Disease Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030, (USD Billion)
  • 5.4. Clinics
    • 5.4.1. Clinic market estimates and forecasts, 2018 to 2030, (USD Billion)
  • 5.5. Others
    • 5.5.1. Other market estimates and forecasts, 2018 to 2030, (USD Billion)

Chapter 6. Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Infectious Disease Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Novartis AG
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Gilead
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. GlaxoSmithKline plc
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Janssen Pharmaceutical, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. F. Hoffmann-La Roche Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. BioCryst Pharmaceuticals, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Merck & Co., Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Boehringer Ingelheim GmbH
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives